Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection

CONCLUSIONS: Tocilizumab in early stages of the inflammatory flare could reduce an important number of ICU admissions and mechanical ventilation. The mortality rate of 10.3% among patients receiving tocilizumab appears to be lower than other reports. This is a non-randomized study and the results should be interpreted with caution.PMID:33829722 | DOI:10.37201/req/037.2021

Source: Revista Espanola de Quimioterapia - April 8, 2021 Category: Drugs & Pharmacology Authors: E Moreno-Garc ía E Rico L Albiach D Ag üero J Ambrosioni M Bodro C Cardozo M Chumbita M De la Mora N Garc ía-Pouton C Garcia-Vidal A Gonz ález-Cordón M Hern ández-Meneses A Inciarte M Laguno L Leal L Linares I Macay F Meira J Mensa A Moreno L Morata Source Type: research